At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
GLPG3970 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
In Brief
A Phase 2 clinical trial evaluating GLPG3970 and Placebo for Rheumatoid Arthritis. Completed, enrolled 28 participants across 9 sites in 4 countries.
Detailed Summary
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria, Georgia, Poland, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartOct 2020
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedOct 8, 2020
Enrollment StartOct 12, 2020
Primary CompletionMar 26, 2021
Study CompletionApr 7, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.7 years ago
Interventions
GLPG3970drug
GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
Placebodrug
Placebo powder and solvent for oral solution to be reconstituted prior to use.